Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 13 04:00PM ET
91.86
Dollar change
-0.52
Percentage change
-0.57
%
IndexNDX, S&P 500 P/E1035.57 EPS (ttm)0.09 Insider Own0.10% Shs Outstand1.25B Perf Week-0.30%
Market Cap113.83B Forward P/E12.13 EPS next Y7.57 Insider Trans-29.43% Shs Float1.24B Perf Month-0.84%
Income126.00M PEG110.66 EPS next Q1.72 Inst Own85.34% Short Float1.88% Perf Quarter10.46%
Sales28.27B P/S4.03 EPS this Y-34.72% Inst Trans0.47% Short Ratio3.46 Perf Half Y41.19%
Book/sh14.83 P/B6.19 EPS next Y72.59% ROA0.22% Short Interest23.41M Perf Year10.55%
Cash/sh5.40 P/C17.00 EPS next 5Y9.36% ROE0.62% 52W Range62.07 - 98.90 Perf YTD13.39%
Dividend Est.3.06 (3.34%) P/FCF12.07 EPS past 5Y1.55% ROI0.32% 52W High-7.12% Beta0.20
Dividend TTM3.83 (4.17%) Quick Ratio1.10 Sales past 5Y4.16% Gross Margin77.96% 52W Low47.99% ATR (14)2.12
Dividend Ex-DateDec 13, 2024 Current Ratio1.26 EPS Y/Y TTM-97.87% Oper. Margin37.45% RSI (14)52.39 Volatility2.52% 2.25%
Employees18000 Debt/Eq1.26 Sales Y/Y TTM3.72% Profit Margin0.45% Recom1.97 Target Price99.21
Option/ShortYes / Yes LT Debt/Eq1.16 EPS Q/Q-42.06% Payout66.62% Rel Volume1.02 Prev Close92.38
Sales Surprise7.55% EPS Surprise32.03% Sales Q/Q7.05% EarningsNov 06 AMC Avg Volume6.78M Price91.86
SMA200.76% SMA502.29% SMA20020.06% Trades Volume6,889,644 Change-0.57%
Date Action Analyst Rating Change Price Target Change
Dec-10-24Resumed BofA Securities Buy $109
Nov-15-24Initiated Wolfe Research Outperform $110
Nov-14-24Initiated Citigroup Buy $125
Nov-08-24Downgrade Maxim Group Buy → Hold
Oct-21-24Upgrade Leerink Partners Market Perform → Outperform $74 → $96
Oct-17-24Initiated Bernstein Outperform $105
Oct-07-24Upgrade Wells Fargo Equal Weight → Overweight $78 → $100
Jul-08-24Upgrade Raymond James Mkt Perform → Outperform $93
May-01-24Reiterated Maxim Group Buy $90 → $85
Apr-24-24Upgrade HSBC Securities Reduce → Hold $69
Dec-13-24 05:50PM
12:15PM
06:37AM
Dec-12-24 05:54PM
05:30PM
01:13PM Loading…
01:13PM
09:40AM
09:00AM
07:00AM
Dec-09-24 05:45PM
04:30PM
04:22PM
Dec-08-24 12:30PM
Dec-05-24 04:00AM
Dec-03-24 09:30AM
07:00AM Loading…
07:00AM
Dec-02-24 07:45AM
Nov-28-24 05:05PM
09:00AM
07:07AM
Nov-27-24 05:00PM
Nov-26-24 09:40AM
07:43AM
Nov-22-24 06:35AM
Nov-18-24 09:47AM
12:42AM
Nov-15-24 02:14PM
11:00AM
Nov-14-24 09:54AM
09:30AM
09:00AM Loading…
09:00AM
Nov-13-24 08:24PM
06:45AM
12:04AM
Nov-12-24 05:30AM
Nov-10-24 09:30AM
Nov-08-24 04:05PM
09:34AM
Nov-07-24 04:04PM
01:46PM
12:57PM
10:01AM
09:34AM
08:30AM
02:20AM
Nov-06-24 09:00PM
06:00PM
05:15PM
04:52PM
04:19PM
04:13PM
04:02PM
04:01PM
12:26PM
Nov-05-24 07:19PM
09:15AM
Nov-04-24 05:53PM
Nov-03-24 07:00AM
Nov-01-24 09:15AM
Oct-31-24 05:50PM
09:00AM
06:00AM
Oct-30-24 10:01AM
Oct-29-24 06:00PM
Oct-24-24 08:15AM
Oct-23-24 06:00PM
Oct-22-24 12:36PM
09:00AM
Oct-21-24 12:28PM
Oct-19-24 05:09PM
11:57AM
Oct-18-24 02:34PM
08:50AM
Oct-17-24 09:00AM
Oct-15-24 06:00PM
Oct-14-24 10:01AM
Oct-10-24 07:22PM
Oct-09-24 05:52PM
04:05PM
08:30AM
Oct-08-24 06:00PM
09:25AM
Oct-07-24 11:00AM
02:52AM
Oct-03-24 09:00AM
04:52AM
Oct-02-24 10:43AM
08:30AM
Oct-01-24 06:00PM
Sep-25-24 09:55AM
Sep-24-24 06:00PM
Sep-23-24 04:06PM
02:12PM
09:38AM
Sep-21-24 12:00PM
07:36AM
Sep-19-24 09:00AM
Sep-18-24 01:30PM
Sep-17-24 06:00PM
Sep-16-24 06:00AM
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Dickinson Andrew DChief Financial OfficerNov 29 '24Option Exercise70.50248,64517,528,577387,564Dec 03 02:43 PM
Dickinson Andrew DChief Financial OfficerNov 29 '24Sale92.76248,64523,065,271138,919Dec 03 02:43 PM
Parsey MerdadChief Medical OfficerNov 27 '24Option Exercise62.44145,4139,079,689245,012Nov 29 08:10 PM
Parsey MerdadChief Medical OfficerNov 27 '24Sale91.92164,21115,094,01380,801Nov 29 08:10 PM
ANDREW DICKINSONOfficerNov 29 '24Proposed Sale92.76248,64523,065,258Nov 29 02:35 PM
Bluestone JeffreyDirectorNov 26 '24Option Exercise61.2410,000612,44215,708Nov 27 06:14 PM
Bluestone JeffreyDirectorNov 26 '24Sale91.396,788620,3568,920Nov 27 06:14 PM
MERDAD V PARSEYOfficerNov 27 '24Proposed Sale91.92164,21115,094,008Nov 27 04:15 PM
Bluestone JeffreyDirectorNov 26 '24Proposed Sale91.396,788620,356Nov 26 07:31 PM
Mercier JohannaChief Commercial OfficerNov 06 '24Sale91.285,000456,40073,127Nov 07 04:38 PM
Parsey MerdadChief Medical OfficerNov 06 '24Option Exercise57.9225,0001,448,000125,189Nov 07 04:32 PM
Parsey MerdadChief Medical OfficerNov 06 '24Sale91.5025,5902,341,48599,599Nov 07 04:32 PM
MERDAD V PARSEYOfficerNov 06 '24Proposed Sale91.5025,5902,341,485Nov 06 04:19 PM
JOHANNA MERCIEROfficerNov 06 '24Proposed Sale91.285,000456,400Nov 06 04:07 PM
Parsey MerdadChief Medical OfficerOct 01 '24Sale83.832,000167,660100,189Oct 02 04:58 PM
MERDAD V PARSEYOfficerOct 01 '24Proposed Sale83.832,000167,660Oct 01 04:27 PM
Parsey MerdadChief Medical OfficerSep 12 '24Option Exercise57.9225,0001,448,000123,435Sep 13 07:07 PM
Parsey MerdadChief Medical OfficerSep 12 '24Sale84.5021,2461,795,287102,189Sep 13 07:07 PM
Mercier JohannaChief Commercial OfficerSep 12 '24Sale83.7829,3572,459,57778,127Sep 13 05:08 PM
MERDAD V PARSEYOfficerSep 12 '24Proposed Sale84.5021,2461,795,287Sep 12 04:45 PM
JOHANNA MERCIEROfficerSep 12 '24Proposed Sale83.7829,3572,459,577Sep 12 04:43 PM
Mercier JohannaChief Commercial OfficerAug 28 '24Sale78.039,513742,299105,466Aug 29 03:23 PM
JOHANNA MERCIEROfficerAug 28 '24Proposed Sale78.039,513742,299Aug 28 04:18 PM
Mercier JohannaChief Commercial OfficerAug 13 '24Sale73.985,490406,150114,979Aug 14 02:23 PM
JOHANNA MERCIEROfficerAug 13 '24Proposed Sale73.985,490406,150Aug 13 04:27 PM
Parsey MerdadChief Medical OfficerJul 01 '24Sale68.632,000137,26096,380Jul 01 08:06 PM
GILEAD SCIENCES, INC.10% OwnerApr 02 '24Buy0.76485,250368,7907,345,473Apr 03 06:50 PM
Parsey MerdadChief Medical OfficerApr 01 '24Sale72.962,000145,92096,304Apr 02 06:38 PM
Parsey MerdadChief Medical OfficerFeb 29 '24Sale72.748,230598,62492,706Feb 29 06:35 PM
Parsey MerdadChief Medical OfficerFeb 28 '24Sale73.182,000146,360100,936Feb 29 06:35 PM
GILEAD SCIENCES, INC.10% OwnerFeb 12 '24Buy22.00910,00020,020,0004,126,119Feb 13 05:48 PM
GILEAD SCIENCES, INC.10% OwnerJan 29 '24Buy21.0015,238,095319,999,99530,061,124Jan 31 05:00 PM
Dickinson Andrew DChief Financial OfficerJan 16 '24Sale85.785,000428,900101,534Jan 17 06:01 PM
Mercier JohannaChief Commercial OfficerJan 09 '24Sale85.238,242702,46682,729Jan 10 03:58 PM